During pregnancy, insulin-like growth factors (IGFs) are important for growth of fetal and maternal tissues. One of the IGF binding proteins, IGFBP-1, is thought to regulate their activity within the local environment of the placenta. IGFBP-1 usually exists as a phosphorylated, high affinity species, which sequesters IGFs, thereby inhibiting their actions. This study has investigated the mechanisms that release IGF from IGFBP-1 at the maternal-fetal interface. Under basal conditions, human decidualized endometrium produces both non-phosphorylated (np) and phosphorylated (p) isoforms of IGFBP-1; however, in the presence of IGF-II, which is a trophoblast secretory product, npIGFBP-1 was preferentially produced. Furthermore, we found that trophoblast, presumably via placental alkaline phosphatase, can de-phosphorylate pIGFBP-1. Since npIGFBP-1 has decreased affinity for IGF-I, these effects should enhance IGF-I bioavailability. In addition, we found that decidual cells produce a protease, which cleaves IGFBP-1, but only when it is non-phosphorylated; [ 125 I]-npIGFBP-1 is proteolysed into 14 and 17 kDa fragments which have markedly reduced affinity for IGF. We therefore propose paracrine modulation of IGFBP-1 at the maternal-fetal interface involving a multi-step process of de-phosphorylation and proteolysis; this will result in enhanced IGF bioavailability and is likely to represent an important mechanism for controlling fetal and maternal tissue growth.
Introduction
absent from decidualized endometrium; however IGFBP-1, an important IGF binding protein in pregnancy, is a major Insulin-like growth factors (IGFs) and the binding proteins secretory product of decidual cells (Waites et al., 1988) . It is (IGFBPs) that control their activity are crucial for fetal growth also the predominant IGFBP in amniotic fluid (Drop et al., and development . This is shown by studies in mice, where 1984), a major IGF binding species in fetal plasma (Drop ablation of either the IGF-I or IGF-II gene reduces fetal size et al., 1984) and its concentrations are increased in the maternal to 60% that of normal littermates (Powell et al., 1993) . If both circulation during pregnancy. At term, maternal (Howell et al. , genes are knocked out, then pup size is reduced to 30% (Liu 1985) and fetal IGFBP-1 (Verhaeghe et al., 1993 (Verhaeghe et al., ) concentraet al., 1993 . In humans, the IGF axis is disrupted in disorders tions are negatively correlated with birth weight and in of fetal growth; IGF-I concentrations are decreased in cord pregnancies complicated by IUGR or pre-eclampsia, raised sera from intra-uterine growth restricted (IUGR) or small for maternal and fetal IGFBP-1 concentrations have been observed gestational age (SGA) fetuses (Giudice et al., 1995) and are (Giudice et al., 1997) . These studies all point to a role for increased in large for gestational age (LGA) newborns (Giudice IGFBP-1 as a local modulator of IGF action in fetal growth. et al., 1995) .
In addition, IGFBP-1 may be able to have IGF-independent Successful fetal growth requires a developmentally and effects, since it has an RGD sequence which can interact with functionally adequate maternal-fetal interface (Han, 1993) .
the α 5 β 1 integrin present on cytotrophoblast cells (Irwin and Han et al. (1996) have shown that IGF-I and IGF-II, though . especially the latter, are present in placental trophoblasts and
We have shown that, in the circulation, IGFBP-1 fetal membranes from as early as 6 weeks. IGF-II expression normally exists in a highly phosphorylated state (pIGFBP-1) is most abundant in the trophoblastic columns of the anchoring (Westwood et al., 1994) . However, during pregnancy, we found villi, particularly in cells at the leading edge of the column, non-phosphorylated isoforms of IGFBP-1 (npIGFBP-1) in the suggesting that IGF-II may have a role in trophoblast invasion of the endometrium (Han et al., 1996) . Both peptides are maternal circulation (Westwood et al., 1994) . Since pIGFBP-1 (Westwood et al., 1994) . Samples (adjusted to contain equal protein has a higher affinity for IGF-I than npIGFBP-1 (Jones et al., concentrations) were incubated with anti-IGFBP-1 (6303; a kind gift 1991; Westwood et al., 1997) , changes in IGFBP-1 phospho- (Westwood et al., 1997) and, hence, promoting the antibody was separated by centrifugation for 10 min and the precipitpresence of npIGFBP-1 at the fetal-maternal interface will not ated proteins were washed in PBS/0.25% bovine serum albumin affect the actions of the predominant IGF at this site.
(BSA)/0.1% Tween 20 prior to resuspension in gel loading buffer.
Another mechanism for releasing IGFs from binding proteins All samples were then boiled for 5 min. Electrophoresis was performed is proteolysis. Pregnancy-associated proteolysis of several using stacking (4%) and resolving (12%) gels containing 20 mmol/l other binding proteins, particularly IGFBP-3, has been compreof the non-ionic detergent n-octyl glucoside (n-OG). Following overnight transfer onto nitrocellulose membranes, proteins were hensively described (Davies et al., 1991) . These binding revealed by incubation with 150 000 cpm/ml [ 125 I]-IGF-I (4 h at proteins are cleaved within the maternal circulation by enzymes 25°C) and autoradiography.
that appear to have no affect on IGFBP-1. However, plasmin (Frost et al., 1993 ), stromelysin-3 (Manes et al., 1997 and
Radioimmunoassay of IGFBP-1
The concentrations of IGFBP-1 produced by decidualized endometrial amniotic fluid (Binoux et al., 1994) do have IGFBP-1 proteocells in response to 7 days incubation with 0-500 ng/ml IGF-I, lytic activity, though little is known of the physiological IGF-II or insulin were determined using our previously reported relevance of an IGFBP-1 protease.
radioimmunoassay which measures all isoforms of IGFBP-1
This study aimed to investigate mechanisms for producing (Westwood et al., 1997) . Unless otherwise stated all chemicals used npIGFBP-1 at the fetal-maternal interface and to explore the were obtained from Sigma.
possibility that IGFBP-1 proteolysis at this site might be a
Purification of highly phosphorylated IGFBP-1 mechanism for increasing IGF-II bioavailability.
Highly phosphorylated IGFBP-1 was purified as previously described (Westwood et al., 1997) from plasma donated by healthy female subjects taking a combined oral contraceptive pill, since circulating
Materials and methods
concentrations of this isoform are elevated in these subjects (Westwood Tissues and cell culture et al., 1999) . Unless otherwise stated all chemicals used were obtained from Sigma.
Human first trimester decidualized endometrial cells Samples of normal human first trimester decidua parietalis (8-12
IGFBP-1 protease assay weeks gestation) were obtained (with local ethical committee approval) after termination of pregnancy and carefully examined
To determine whether IGFBP-1 is susceptible to proteolysis, samples under a dissecting microscope to ensure absence of villous material.
reflecting IGFBP-1 sites of synthesis (conditioned medium from In accordance with our previously described method (Vicovac HepG2 and first trimester decidual cells) or potential target tissues et al., 1994), decidual tissue was incubated at 37°C with 0.02%
[conditioned medium from first trimester trophoblast and 3T3-L1 protease for 15 min followed by 0.2% hyaluronidase and 0.25% adipocytes (pre-and post-differentiation)] were analysed on three collagenase for 2 h. The resulting suspension was filtered initially occasions using a method based on an IGFBP-3 protease assay through a 100 µm nylon sieve to remove undigested tissue fragments (Lamson et al., 1991) . Normal plasma, pregnancy plasma, amniotic and then through a 40 µm sieve to retain whole glands and cell fluid and plasmin (0.025 IU) were used as controls (Frost et al., aggregates as previously shown for endometrium. Cells were then 1993; Binoux et al., 1994) . Briefly, 30 000 cpm [ 125 I]-recombinant resuspended in 25% Percoll (Amersham Pharmacia Biotech UK Ltd, human IGFBP-1 (iodinated by the chloramine T method) was Bucks, UK), and layered over 60% Percoll. After centrifugation at incubated with a 5-40 µl sample in 0.5 mmol/l calcium chloride/PBS 670 g for 30 min, cells at the 25/60% interface were collected, for 16 h at 37°C. The reaction was stopped by the addition of gel washed three times in phosphate-buffered saline (PBS), counted and loading buffer and boiling for 5 min and the samples were subjected plated at 0.5ϫ10 6 /well in 6-well plates. Cultures were maintained in to sodium dodecyl sulphate (SDS) electrophoresis (15% resolving Dulbecco's modified Eagle's medium (Sigma, Poole, Dorset, UK) gel) and autoradiography. (DMEM)/10% fetal calf serum (FCS)/100 µg/ml streptomycin (Sigma) and 100 IU/ml penicillin Sigma at 37°C in 5% CO 2 . Cultures were Characterization of IGFBP-1 protease established on three separate occasions and each variable was tested
To characterize the IGFBP-1 protease present in decidual cell condiin triplicate.
tioned medium, samples were incubated as described above in the presence of a range of protease inhibitors (Boehringer Manheim,
BeWo choriocarcinoma cells
Lewes, East Sussex). In addition, zymography was used to estimate BeWo cells were obtained from the European Collection of Animal the molecular weight of the protease. Samples were electrophoresed Cell Culture (Porton Down, UK). They were cultured in an equal through a 10% poly-acrylamide/SDS gel containing 2 µg/ml recombinmixture of DMEM and Ham's F12 containing 10% FCS, 2 mmol/l ant human IGFBP-1. 50 mmol/l Tris, pH 8.0/5 mmol/l CaCl 2 was glutamine, 5 µg/ml gentamicin and 100 µg/ml streptomycin at 37°C used to activate the protease and simultaneously transfer the IGFBP-1 in 5% CO 2 .
fragments to polyvinyldifluoridine (PVDF) membranes by capillary action (24 h at 37°C). The fragments were then visualized by Western Methods immunoblotting.
Biochemical characterization of IGFBP-1 phosphorylation status
Western immunoblotting IGFBP-1 phosphorylation status was determined using our previously described method of immunoprecipitation followed by Non-specific binding was blocked by incubating membranes with 0.15 mol/l NaCl/1% BSA for 1 h at room temperature. They were n-octyl glucoside electrophoresis and Western ligand blotting then exposed to a 1/1000 dilution of anti-IGFBP-1 antibody (6303 sure to trophoblast cells; BeWo cells were cultured (n ϭ or 6305) for 4 h at 25°C, followed by anti-mouse IgG linked to 3) with 100 ng/ml highly phosphorylated IGFBP-1; n-OG horseradish peroxidase for 2 h. Chemiluminescence (ECL, Amersham, electrophoresis and Western ligand blotting was used to analyse UK) was used to reveal bound antibody. the conditioned medium. Figure 2 demonstrates that after 24 h, non-and lesser-phosphorylated isoforms appeared. Direct
Effect of IGFBP-1 phosphorylation status on proteolysis
exposure to cells is necessary for de-phosphorylation to occur;
Normal human plasma was used as the source of phosphorylated incubation of highly phosphorylated IGFBP-1 with BeWo IGFBP-1. This was found by radioimmunoassay (Westwood et al., conditioned medium did not result in production of non-and 
Proteolysis of IGFBP-1 at the maternal-fetal interface
Recombinant IGFBP-1, used as the non-phosphorylated isoform, was spiked at 200 µg/l into plasma stripped of endogenous IGFBP-1
Source of IGFBP-1 protease
by immunoaffinity chromatography (Westwood et al., 1997) . Both IGFBP proteolysis is a well-recognized mechanism for IGFBP-1 preparations were incubated with decidual conditioned controlling IGF bioavailability yet little is known about the medium (50 µl) or plasmin (0.025 IU) for 16 h at 37°C and then the susceptibility of IGFBP-1 to enzymatic cleavage. Therefore contain proteases for other IGFBPs (amniotic fluid, pregnancy and normal serum; Davies et al., 1991; Claussen et al., 1994) .
Results
Plasmin was used as a positive control (Frost et al., 1993) . . In order to investigate the mechanisms controlling producdualized endometrial cells or Hep G2 cells. Trophoblast, tion of these isoforms, decidual cells were incubated for 7 fibroblasts and adipocytes appear not to produce an IGFBP-1 days with factors (IGF-I, IGF-II and insulin; 0-500 ng/ml) protease and unlike other IGFBPs, IGFBP-1 was not cleaved known to regulate IGFBP-1 concentrations (Thrailkill et al., when incubated with pregnancy or normal sera. 1990; . In each of three experiments Specificity of IGFBP-1 protease all of the factors stimulated IGFBP-1 production at lower In order to determine whether the phosphorylation status concentrations, but inhibited IGFBP-1 productions at higher of IGFBP-1 affects its susceptibility to proteolysis, plasma concentrations ( Figure 1B ). More interesting however, was containing either npIGFBP-1 or pIGFBP-1 at 200 µg/l was our observation that these factors had a differential effect on incubated on three occasions with conditioned medium from IGFBP-1 phosphorylation status ( Figure 1A) . In response decidualized endometrial cells or plasmin at 37°C overnight. to IGF-II, the predominant IGF produced by trophoblast,
The fate of the IGFBP-1 isoforms was then investigated decidualized endometrial cells produced relatively more nonby Western immunoblotting. Figure 4 shows that non-phosphosphorylated IGFBP-1 than the highly phosphorylated isophorylated IGFBP-1 is completely proteolysed by the protease form (Figure 1 ), whereas neither IGF-I ( Figure 1A ) nor insulin activity in decidual conditioned medium or by plasmin. In (data not shown) had this effect.
contrast, pIGFBP-1 is resistant to both proteases.
IGFBP-1 production and modulation by trophoblast cells IGFBP-1 was not detectable by RIA in medium conditioned
Characterization of IGFBP-1 protease Substrate zymography and inhibitor studies were performed by first trimester villous trophoblast explants, differentiating term cytotrophoblasts (24 and 96 h) nor BeWo chorioin order to learn more about the IGFBP-1 protease activity present in amniotic fluid and conditioned medium from carcinoma cells, confirming that human trophoblasts do not produce IGFBP-1 (Han et al., 1996) . However, in the light of decidual cells. Figure 5 shows that decidual conditioned medium contains an IGFBP-1 protease that co-migrates with the results described above, we considered other mechanisms by which trophoblast could modulate decidual cell IGFBPplasmin. In addition, both decidual medium and amniotic fluid contain high molecular weight proteases of 100-200 kDa. 1 in order to increase the presence of npIGFBP-1 in the paracrine environment. Trophoblast and BeWo cells express When [ 125 I]-IGFBP-1 was incubated with amniotic fluid or conditioned medium from decidual cells in the presence of placental alkaline phosphatase (PLAP) and thus we investigated whether IGFBP-1 phosphorylation status was altered on expoinhibitors of aspartate, cysteine, serine or metalloproteases, both activities were sensitive to inhibitors of serine proteases in the appearance of fragments with a molecular weight of 17 kDa and that this proteolysis can be inhibited with PMSF. [chymostatin, 4-(2-aminoethyl)benezenesulfonyl fluoride (AEBSF) and phenyl methyl sulphonyl fluoride (PMSF)],
The ligand blot shown in Figure 7 demonstrates that when the same blot is probed with a mixture of [ 125 I]-IGF-I and [ 125 I]-while the activity in decidual conditioned medium was also partially inhibited by the metalloprotease inhibitor, EDTA IGF-II, these ligands bind intact IGFBP-1 but not the 17 kDa fragments. (Figure 6 ). Neither antipain, bestain, E-64, leupeptin, pepstatin, phosphoramidon, nor aprotinin inhibited the digestion of [ 125 I]-IGFBP-1 in any of the three experiments performed.
Discussion

Consequences of IGFBP proteolysis
In order to determine whether proteolysis of IGFBP-1 could This study supports the hypothesis of IGF/IGFBP interactions at the feto-maternal interface. We have shown that decidual have physiological consequences for IGF bioavailability, the protease from decidual cell conditioned medium was allowed IGFBP-1 production and phosphorylation status is regulated by factors known to be in the paracrine environment, resulting to cleave the endogenous IGFBP-1 by incubating the medium overnight at 37°C. IGFBP-1 was then analysed by Western in the predominance of an IGFBP-1 isoform which has an increased susceptibility to proteolysis and hence the potential ligand and immunoblotting. The representative (n ϭ 3) immunoblot depicted in Figure 7 shows that the majority of for increased IGF bioavailability. Both IGF-I and IGF-II mRNA, the latter in greater abund-IGFBP-1 in decidua-conditioned medium is cleaved resulting ance, are present at the feto-maternal interface and are reported also signals through this receptor did not have a similar effect on decidual IGFBP-1 phosphorylation status. Recent data has to be entirely of fetal origin (Wang et al., 1988; Zhou and Bondy, 1992; Han et al., 1996) . We, like others, have found demonstrated that IGF-II can signal through the type 2 IGF receptor in endometrial epithelial cells (Badinga et al., 1999 ) that both these peptides regulate the concentrations of IGFBP-1 produced by decidualized endometrial cells. However, our and there is evidence from the IGF knock-out studies to suggest that in placenta, IGF-II signalling is mediated, at least study has also shown a differential effect on the phosphorylation status of IGFBP-1, with increased concentrations of the in part, by mechanisms independent of the type 1 IGF receptor . non-phosphorylated isoform in the presence of IGF-II but no difference with IGF-I. The signalling pathway by which IGFWhatever the mechanism of IGF-II signalling, it is not clear whether the increase in npIGFBP-1 is caused by modification II mediates this increase in npIGFBP-1 production by decidual cells has not been investigated, but our data suggests that it of intracellular kinase pathways or by increasing extracellular de-phosphorylation. The fact that decidual cells express does not involve the type1 IGF receptor since IGF-I, which mechanism for controlling phosphorylation status merits further investigation.
Increased IGF-I bioavailability may be necessary for decidua or trophoblast growth and metabolism. IGF-I stimulates nutrient transport across the placenta (Kniss et al., 1994) and recently, it has been demonstrated that this is affected by IGFBP-1 phosphorylation status (Yu et al., 1998) ; npIGFBP-1 enhanced IGF-I stimulated [ 3 H]-γ-amino isobutyric acid uptake by human trophoblast cells whilst phosphorylated IGFBP-1 inhibited this effect. In addition, we have recently found that in type 1 diabetic pregnancy, elevated phos- Western immunoblotting. Non-phosphorylated IGFBP-1 was cleaved by both sources of proteolytic activity whereas the We have also found that changing IGFBP-1 phosphorylation phosphorylated isoform was resistant to proteolysis. This blot is status does not affect its affinity for IGF-II (Westwood et al., shown as a representative of three experiments. 1997), the predominant IGF peptide at the fetal-maternal interface, which led us to look for another mechanism for increasing IGF-II bioavailability. Proteolysis of the other IGFBPs, is an important mechanism for regulating IGF actions, yet apart from a report of an IGFBP-1 protease in amniotic fluid (Binoux et al., 1994) , little is known about cellular IGFBP-1 proteolysis. Our study has shown that as well as amniotic fluid, medium conditioned by decidualized endometrial but not trophoblast cells contains a protease capable of cleaving IGFBP-1 into fragments which do not bind to IGF in Western ligand blot analysis. However, we also found that IGFBP-1 is only susceptible to proteolysis when it is in the non-phosphorylated state.
Therefore, we propose a model in which trophoblast and decidua act in mutual harmony to direct IGF bioavailability in the local environment. We propose that maternal decidua is further the preponderance of non-phosphorylated IGFBP-1 by de-phosphorylating circulating pIGFBP-1. We speculate that this will increase IGF-I bioavailability, which, as discussed, alkaline phosphatase (Galski et al., 1982) and that highly phosphorylated IGFBP-1 isoform is still detectable in medium may be important for regulating metabolism at the fetalmaternal interface. In addition it will also act as a mechanism conditioned by cells cultured with IGF-II, support the latter hypothesis.
for making IGFBP-1 susceptible to proteolysis by an enzyme produced in the maternal decidualized endometrium. We have We also demonstrated that trophoblast cells can dephosphorylate the highly phosphorylated variant of IGFBP-1.
found that like other IGFBPs, once cleaved, IGFBP-1 can no longer bind IGF and this may therefore be a way of increasing Trophoblast (Webb et al., 1985) and BeWo (unpublished observations) express placental alkaline phosphatase and it the bioavailability of IGF-II as well as IGF-I. Recently, Manes et al. have shown that in contrast to intact IGFBP-1, IGFBP-1 may be via this enzyme, that trophoblast can increase the concentrations of non-phosphorylated IGFBP-1 and thus IGF-I fragments generated by stromelysin-3 cannot inhibit IGF-induced proliferation in breast adenocarcinoma cells bioavailability at the feto-maternal interface. De-phosphorylation occurred only if the IGFBP-1 was directly exposed to cells.
( Manes et al., 1997) . We have not assessed the extent of IGFBP-1 proteolysis in vivo, though obviously not all IGBP-1 This may simply be because placental alkaline phosphatase (a GPI-anchored protein) is not released into medium by these is cleaved since intact IGFBP-1 can be detected in amniotic fluid and our decidual cell cultures. This poses interesting cells or, more interestingly, it may imply that IGFBP-1 must be localized to the cell surface in order for de-phosphorylation questions regarding the control of proteolysis and may suggest the presence of inhibitors. Alternatively, the ratio of intact to to occur. IGFBP-1 has an RGD site and can interact with the α 5 β 1 integrin present on trophoblast and this potential fragmented IGFBP-1 may depend on the balance between IGFBP-1 production/transport and proteolysis. Nonetheless, circulation. Furthermore, other authors (Irwin et al., 2000) have recently reported a trophoblast-derived IGFBP-3 protease since IGFBP-1 is the predominant IGF binding species at the maternal-fetal interface, even small changes to the proportion which is inactive towards IGFBP-1 and it has been suggested that individual enzymes are specific for each of the binding of proteolysed IGFBP-1 could have significant consequences for IGF bioavailability.
proteins (Maile and Holly, 1999) . Additionally, proteolysis of IGFBP-1 may provide a mechan-IGFBP proteolysis may be a general feature of pregnancy, since IGFBP-3 is proteolysed in the maternal circulation, ism for regulating some IGF-independent action of IGFBP-1. Non-phosphorylated IGFBP-1 has been shown to increase presumably to increase IGF activity in order to meet the increased metabolic demands placed on the mother, and CHO cell migration via its RGD interaction with α 5 β 1 integrin (Jones et al., 1993) , though whether or not this affect extends the proportion of IGFBP-1 in the non-phosphorylated form in the maternal circulation could contribute to this phenomenon.
to the migration of trophoblast is controversial. IGFBP-1 has been reported to stimulate human trophoblast cell migration However, there are clearly different enzymes involved in the protolysis of the two binding proteins, since in our study, and invasion, both independently and by enhancing IGF-II actions (Irving and Lala, 1995; Hamilton et al., 1998) . If true, pregnancy plasma did not cleave [ 125 I]-IGFBP-1 and we could not detect the presence of IGFBP-1 fragments in the maternal then proteolysis of IGFBP-1 may be necessary for curbing though studies to identify the relevant proteases for IGFBP-1 action at this site are in progress. In summary we have shown that decidualized endometrial cells produce both highly phosphorylated and non-phosphorylated IGFBP-1. Both IGF-I and IGF-II regulate IGFBP-1 production but only IGF-II can influence phosphorylation status by preferentially increasing npIGFBP-1 concentrations. NpIGFBP-1 is susceptible to a protease produced by decidualized endometrium and this results in IGFBP-1 fragments which do not bind IGF. We therefore propose a paracrine interaction in which trophoblast-directed modulation of IGFBP-1 regulates actions of the IGF axis at the feto-maternal interface.
